Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
作者： David M. Gershenson , Charlotte C. Sun , Karen H. Lu , Robert L. Coleman , Anil K. Sood
DOI: 10.1097/01.AOG.0000227787.24587.D1
关键词: Hazard ratio 、 Survival analysis 、 Gastroenterology 、 Serous carcinoma 、 Ovary 、 Metastasis 、 Cystadenocarcinoma 、 Medicine 、 Surgery 、 Internal medicine 、 Stage (cooking) 、 Chemotherapy
摘要: … stroma (to differentiate low-grade serous carcinomas from serous tumors of low malignant … 23 compared the molecular profiles of four low-grade serous carcinomas with eight grade 3 …
lww.com
sci-hub.se 参考文章(37)
A. Talerman, F. A. Langley, J. F. M. Delemarre, J. P. A. Baak, Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Analytical and Quantitative Cytology and Histology. ,vol. 8, pp. 354- 357 ,(1986)
Jeffrey D Seidman, Robert A Soslow, Russell Vang, Jules J Berman, Mark H Stoler, Mark E Sherman, Esther Oliva, Andre Kajdacsy-Balla, David M Berman, Larry J Copeland, Borderline ovarian tumors: Diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images1 1This report contains statements that include a variety of suggestions and recommendations. In view of the wide range of opinions regarding the tumors under discussion, none of these statements is intended as, or should be interpreted as, representing the “standard of care.” Human Pathology. ,vol. 35, pp. 918- 933 ,(2004) , 10.1016/J.HUMPATH.2004.03.004
Franco M. Muggia, Patricia S. Braly, Mark F. Brady, Gregory Sutton, Theodore H. Niemann, Samuel L. Lentz, Ronald D. Alvarez, Paul R. Kucera, James M. Small, Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study Journal of Clinical Oncology. ,vol. 18, pp. 106- 115 ,(2000) , 10.1200/JCO.2000.18.1.106
Maurie Markman, Brian N. Bundy, David S. Alberts, Jeffrey M. Fowler, Daniel L. Clark-Pearson, Linda F. Carson, Scott Wadler, Joshua Sickel, Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group Journal of Clinical Oncology. ,vol. 19, pp. 1001- 1007 ,(2001) , 10.1200/JCO.2001.19.4.1001
P. Bichel, A. Jakobsen, A new histologic grading index in ovarian carcinoma. International Journal of Gynecological Pathology. ,vol. 8, pp. 147- 155 ,(1989) , 10.1097/00004347-198906000-00008
Gad Singer, Ie-Ming Shih, Alexander Truskinovsky, Haldun Umudum, Robert J. Kurman, Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). International Journal of Gynecological Pathology. ,vol. 22, pp. 37- 41 ,(2003) , 10.1097/00004347-200301000-00009
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Steven G Silverberg, Debra A Bell, Robert J Kurman, Jeffrey D Seidman, Jaime Prat, Brigitte M Ronnett, Larry Copeland, Elvio Silva, Fred Gorstein, Robert H Young, Borderline ovarian tumors: Key points and workshop summary Human Pathology. ,vol. 35, pp. 910- 917 ,(2004) , 10.1016/J.HUMPATH.2004.03.003
R. Tucker Burks, Mark E. Sherman, Robert J. Kurman, Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. The American Journal of Surgical Pathology. ,vol. 20, pp. 1319- 1330 ,(1996) , 10.1097/00000478-199611000-00003
C. Blake Gilks, Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. International Journal of Gynecological Pathology. ,vol. 23, pp. 200- 205 ,(2004) , 10.1097/01.PGP.0000130446.84670.93